The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper

106 AVENUE LOUISE, 1050 BRUSSELS, BELGIUM
Tel:
Work +32 2 500 15 00
Fax:
Fax +32 2 500 16 00
Email:
Web:
www.dlapiper.com

Bertold Bär-Bouyssière

Tel:
Work +32 (0) 2 500 15 35
Email:
DLA Piper LLP (US)

Work Department

Competition law

Position

Dr. Bertold Bär-Bouyssière is one of the leading practitioners of competition law in Brussels and Germany. Bertold has more than 20 years of experience in the field. A partner with DLA Piper’s Brussels and German offices, Bertold is a Fulbright alumnus and admitted to the New York, German and Brussels bars. Bertold currently heads the EU Competition team in Brussels and also has responsibilities as Member of DLA Piper's International Board. In March 2015 he was elected Vice Chair of the AmCham EU Competition Policy Committee where he is also Rapporteur for State aid. Bertold is also the "champion" for DLA Piper's "Life Science Practice" and regularly speaks at international pharma conferences and seminars.


Belgium

Competition: EU and global

Within: Competition: EU and global

DLA Piper's 'impressively engaged and agile' group undertakes competition work for industry-leading corporates across a wide range of industries, with a notable focus on transport, energy, technology and life sciences. It provides 'an in-depth analysis of the issues raised and really tries to get a good understanding of the commercial issues by speaking with business stakeholders'. The firm's global footprint makes it well placed to advise clients located worldwide on the competition aspects of cross-border M&A, distribution law issues, state aid matters and conduct investigations. Practice head Bertold Bär-Bouyssière is representing longstanding client Merck in various contentious matters, including appeals arising from the landmark UK CMA and EC investigations into reverse payment settlements. Bär-Bouyssière provides 'to-the-point advice and has a good sense of humour'. Other names to note are Daniel Colgan, Bob Martens and associate Daniel Wojtczak. Trade and government affairs partner Jeroen Jansen also supports the competition team.

[back to top]

Industry focus: Healthcare and life sciences

Within: Industry focus: Healthcare and life sciences

DLA Piper's life sciences sector group employs a multi-disciplinary approach, assisting its impressive client roster with a range of instructions including corporate, competition, employment, regulatory and IP-related matters. It counts Pfizer and Merck & Co. among its clients, and assisted the former with the coordination of multi-jurisdictional 'pay for delay' litigation, and recently advised the latter on corporate matters. Bertold Bär-Bouyssière and counsel Jean-Louis Kerrels jointly head up the practice.

[back to top]

Germany

Antitrust

Within: Antitrust

With a focus on merger control proceedings before German and European authorities, the ‘quick and service-driven’ team at DLA Piper counts a number of renowned companies such as Merck, Burda and Ergo among its clients. Jan Dreyer, counsel Semin O and Brussels-based Bertold Bär-Bouyssière advised BASF on merger control law matters involved in the acquisition of a competitor; in addition to registration in eleven jurisdictions, the instruction also includes proceedings before the European Commission. The firm also advises energy provider EWE on the foundation of a joint venture with Deutsche Telekom with regards to the expansion of the fibre optic network in north-west Germany. It welcomed counsel Enno Ahlenstiel from Cleary Gottlieb Steen & Hamilton. Michael Holzhäuser is now with Ashurst LLP.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments in Belgium

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to